SAM #75N98026Q01035

NIH NINDS 1-Year Subscription to Illumina DRAGEN GCP Level 4 Platform for Large-Scale Genomic Data Analysis

The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS) Neurodegenerative Diseases Research Section (NDRS), is seeking a 12-month subscription to the Illumina DRAGEN GCP Level 4 platform. - Government Buyer: - Agency: National Institutes of Health (NIH) - Sub-agency: NINDS Neurodegenerative Diseases Research Section (NDRS) - Office: Office of Acquisition and Logistics Management (OALM), Office of Logistics and Operations (OLAO) - OEM and Vendor: - Illumina, Inc. (OEM and sole-source vendor) - Products/Services Requested: - Illumina DRAGEN GCP Level 4 platform 12-month subscription - Quantity: 1 - Purpose: Process approximately 1,300,000 GB of whole-genome sequencing data from 10,000 human genomes - Features: Graph-based alignment to human reference genome (hg38), accurate variant calling (single-nucleotide variants, insertions/deletions, structural variants, copy number variants, repeat expansions) - Compatibility: Must support Illumina-generated sequencing data and existing DRAGEN-processed datasets - Unique/Notable Requirements: - Platform must provide sufficient operational availability and processing capacity to analyze all 10,000 genomes within the 12-month period - Sole-source justification due to proprietary technology and compatibility needs - Estimated contract value: $113,004 - No other OEMs or alternative platforms are specified in the solicitation.

Description

The National Institute of Neurological Disorders and Stroke (NINDS), Neurodegenerative Diseases Research Section (NDRS), requires a 12-month subscription/access to the Illumina DRAGEN GCP Level 4 platform to process approximately 1,300,000 GB of whole-genome sequencing data derived from 10,000 human genomes. The platform must support graph-based alignment to the human reference genome (hg38), accurate variant calling, and detection of single-nucleotide variants, insertions/deletions, structural variants, copy number variants, and repeat expansions.

The platform must be fully compatible with Illumina-generated sequencing data and existing DRAGEN-processed datasets. The contractor shall provide access and operational availability of the DRAGEN GCP platform and processing capability sufficient to analyze the 10,000 genomes during the 12-month period of performance.

View original listing